Clifford Hudis

8PUBLICATIONS
48CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 10, 2025
Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers.

Eric P Winer, Laura A Levit, Ethan Basch

|Jan 02, 2025
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.

Otto Metzger Filho, Karla Ballman, Jordan Campbell

|Jan 19, 2022
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.

Jonathan H Shepherd, Karla Ballman, Mei-Yin C Polley

|Oct 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.

Aranzazu Fernandez-Martinez, Ian E Krop, David W Hillman

|May 06, 2020
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.

Mark P S Dunphy, Christina Pressl, Nagavarakishore Pillarsetty

Pageof 2